Market Cap (In USD)
16.73 Million
Revenue (In USD)
583.23 Thousand
Net Income (In USD)
-14.28 Million
Avg. Volume
8771.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 2.15-8.847
- PE
- -
- EPS
- -
- Beta Value
- 1.735
- ISIN
- US03836J2015
- CUSIP
- 03836J102
- CIK
- 1781983
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Oren Gilad Ph.D.
- Employee Count
- -
- Website
- https://atrinpharma.com
- Ipo Date
- 2019-10-03
- Details
- Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
More Stocks
-
TRCNF
-
PRABHHANSPRABHHANS INDUSTRIES LIMITED
PRABHHANS
-
KESKBHKesko Oyj
KESKBH
-
LGT
-
0U3QInterDigital, Inc.
0U3Q
-
YUYü Group PLC
YU
-
LALPATHLABDr. Lal PathLabs Limited
LALPATHLAB
-
ZLIOY